Abstract | OBJECTIVE:
Bladder pain syndrome (BPS) is a chronic pain condition associated with injury to the glycosoaminoglycan (GAG) layer. We aimed to prospectively evaluate iAluRil® with multi-centre tertiary urogynaecology collaboration. We hypothesised that iAluRil® (a GAG therapy) would demonstrate equivalent symptom, pain and QOL scores compared to DMSO controls. STUDY DESIGN: iAluRil® was administered for 7 instillations over 3 months in 34 women over 6 sites. 18 historical DMSO controls were matched 2:1. At baseline and 3 months post treatment validated questionnaires were collected. RESULTS: Both iAluRil® and DMSO were associated with statistically significant improvements in IC/BPS specific questionnaire scores. iAluRil® showed statistically significant improvements in pain, symptoms, and QOL. 45 % of iAluRil® recipients had a greater than 50 % reduction in pain score as represented by the VAS. DMSO was also effective in improving measures of IC/BPS with statistically significant decreases in ICSI and ICPI. There was no statistically significant difference in the size of the effect between DMSO and IAluRil®. CONCLUSIONS: iAluRil® is well tolerated and associated with significant improvements in pain and symptom scores. Almost half of refractory BPS will have a 50 % decrease in pain score at three months post treatment. This effect size is similar to DMSO.
|
Authors | J Keane, N Young, J Goh, M Atherton, J Yin, K Moore, P Hall, P Higgs, A Leitch, J Lee, A Rosamilia |
Journal | European journal of obstetrics, gynecology, and reproductive biology
(Eur J Obstet Gynecol Reprod Biol)
Vol. 256
Pg. 230-234
(Jan 2021)
ISSN: 1872-7654 [Electronic] Ireland |
PMID | 33248378
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Topics |
- Administration, Intravesical
- Cystitis, Interstitial
(drug therapy)
- Female
- Humans
- Pain
(drug therapy)
- Quality of Life
- Treatment Outcome
|